These data suggest that, despite the immune system being able to mount an anti-cancer response upon checkpoint blockade, resistance mechanisms beyond the CTLA-4 and PD-1 checkpoints may limit cytotoxic T-cell effector function and tumor elimination in these cases. Here, CTLA4 is linked to neoplasm.